The webinar will feature a presentation from Key Opinion Leader (KOL) Stanley C. Jordan, MD (Cedar Sinai), who will discuss the BK Virus (BKV), a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant. BKV is a leading cause of kidney transplant loss and transplant-associated morbidity, yet there are no therapies currently approved to treat BKV.

Vera Therapeutics’ potential treatment solution MAU868, a monoclonal antibody, will also be discussed. MAU868 is the first neutralizing antibody targeting the BK Virus, to which Vera holds an exclusive worldwide license for the development and commercialization in all indications from Pfizer.

A live question and answer session will follow.